|Impax Laboratories Inc.|
30831 Huntwood Avenue
United States - Map
Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Pharmaceuticals Division provides generic pharmaceutical products through its global products sales channel directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies. The Impax Pharmaceutical Division focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinsons disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.
|Impax Laboratories Inc.’s ISS Governance QuickScore as of Oct 1, 2015 is 6. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 2; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. George Frederick Wilkinson ,
Chief Exec. Officer, Pres and Director
|Mr. Bryan M. Reasons ,
Chief Financial Officer and Sr. VP of Fin.
|Mr. Jeffrey D. Nornhold ,
Sr. VP of Technical Operations
|Mr. Mark A. Schlossberg Esq.,
Sr. VP, Gen. Counsel and Sec.
|Mr. Michael J. Nestor ,
Pres of Impax Pharmaceuticals
|Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|